Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SSY Group ( (HK:2005) ) has provided an announcement.
SSY Group Limited has announced that its Vitamin B6 Injection has received approval from the National Medical Products Administration of China for the Consistency Evaluation of the Quality and Efficacy of Generic Drugs. This development signifies a positive step in the company’s product portfolio, potentially enhancing its market position and offering improved treatment options for conditions such as vitamin B6 deficiency and other related ailments.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of generic drugs. The company’s primary products include various pharmaceutical formulations, with a market focus on providing effective and affordable healthcare solutions.
YTD Price Performance: -8.80%
Average Trading Volume: 14,342,383
Technical Sentiment Signal: Hold
Current Market Cap: HK$9.15B
For detailed information about 2005 stock, go to TipRanks’ Stock Analysis page.